FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> MedImmune | FluMist

FluMist can't compete in flu vax study


FluMist just got a big thumb's down in a study reviewing vaccine response in more than a million U.S. soldiers.

Looking over a period of three years, researchers found that the traditional intramuscular flu jab led to a 54 percent reduction in visits to a doctor's office compared with only a 21 percent reduction for the intranasal vaccine FluMist.

FluMist was approved to help guard children from the flu but the New York Times notes that the intranasal vaccine is increasingly popular among adults. But in the 2004-05 flu season adults taking FluMist were even more likely to end up in the hospital than patients who had received no treatment.

Dr. Chris Ambrose, the director of medical affairs for MedImmune, counters that their data indicates a much better response to FluMist among children.  

- read the article in the New York Times

Related Articles:
AZ seeks nasal flu vaccine approval
FDA approves refrigerated formulation of FluMist
Vaccine panel endorses FluMist for toddlers

More stories about MedImmune   FluMist  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.